Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyVentura County 4K Score Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy 001

    4K Score Testing

    Customize your policy alerts

    Sign up for venturacountyhealthcareplan Policy 001 alerts

    Get alerted when Policy 001 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of 4K Score testing used to help determine whether men with elevated PSA levels and/or a suspicious digital rectal exam should proceed to prostate biopsy or MRI. Coverage is subject to the stated patient exclusions and clinical limitations.

    Policy Summary
    PayerVentura County Health Care Plan
    Policy4K Score Testing
    Policy CodePolicy 001
    Change TypeMaterial revision
    Effective DateNov 14, 2019
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionUse 4K Score testing to aid the decision whether to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or a suspicious digital rectal exam.
    SourceLink
    POLICY UPDATE CHANGES

    The intended-use indication was revised to specify use in men with elevated PSA levels and/or a suspicious digital rectal exam.

    The policy identifies OPKO Diagnostics as the only laboratory performing 4K testing.

    4Kallikrein measurements in the 4K Score
    1Laboratory performing 4K testing
    4 daysDRE-free interval before testing
    6 monthsMedication or treatment-free interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10 yearsLife expectancy threshold

    Coverage Criteria

    Covered indication and eligibility

    Covered when all applicable requirements are met:

    Covered 4K Score testing

    • Qualifying clinical indication

      • The patient has elevated PSA levels.
      • The patient has a suspicious digital rectal exam.
    • No listed contraindication: The patient has no previous diagnosis of prostate cancer, no DRE in the previous four days, no 5-alpha-reductase inhibitor therapy within the previous six months, and no invasive treatment for symptomatic benign prostatic hypertrophy within the previous six months.No DRE within 4 days; no 5-alpha-reductase inhibitor therapy or invasive treatment for symptomatic benign prostatic hypertrophy within 6 months

      Testing is rarely indicated in patients with less than 10 years of life expectancy.

    4K Score testing is not intended for patients with a previous diagnosis of prostate cancer, a digital rectal examination (DRE) within the previous 4 days, 5-alpha-reductase inhibitor therapy within the previous 6 months, or invasive treatment for symptomatic benign prostatic hypertrophy within the previous 6 months.

    4K Score testing is rarely indicated for patients with less than 10 years of life expectancy.

    Timing and Utilization Parameters

    Interval after digital rectal exam
    RequirementNo digital rectal exam (DRE) in the previous 4 days
    Restricted eventDigital rectal examination of the prostate
    Coverage implicationTesting is not intended when a DRE occurred within the previous 4 days
    Interval after 5-alpha-reductase inhibitor therapy
    RequirementNo 5-alpha-reductase inhibitor therapy in the previous 6 months
    Restricted event5-alpha-reductase inhibitor therapy
    Coverage implication

    Provider Action Required

    Denial Risk

    Contraindicated Patient or Timing Conditions

    Do not use the test for patients with a previous diagnosis of prostate cancer or when specified recent procedures or therapies may affect the result.

    • Previous diagnosis of prostate cancer
    • DRE performed within the previous 4 days
    • 5α-reductase inhibitor therapy received within the previous 6 months
    • Invasive treatment for symptomatic benign prostatic hypertrophy within the previous 6 months
    Note

    Limited Utility With Short Life Expectancy

    Testing is rarely indicated for patients with a life expectancy of less than 10 years.

    • Life-expectancy threshold: less than 10 years

    Clinical Background

    The 4K Score consists of immunoassays using distinct monoclonal antibodies. It combines measurements of four prostate-specific kallikreins with an algorithm incorporating the patient’s age, digital rectal examination findings, and prior negative prostate biopsy status. The test is intended to support the decision whether to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or a suspicious DRE.

    Key Definitions

    4K Score
    DefinitionA test score based on four prostate-specific kallikrein measurements
    Algorithm inputsPatient age, digital rectal examination findings, and prior negative prostate biopsy status
    DRE findingsThe algorithm distinguishes between nodules and no nodules
    Clinical purposeSupports the decision whether to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or suspicious DRE
    Digital rectal exam (DRE)
    DefinitionA clinical examination of the prostate
    Referenced findings

    Covered Intended Use

    Covered intended indication

    Covered for the following intended use, except in the limited circumstances described below:

    Covered intended use

    • Qualifying clinical finding

      • Elevated PSA levels are present.
      • The digital rectal exam is suspicious.
    • Limited circumstances do not apply: The patient does not have a previous diagnosis of prostate cancer and does not meet any of the specified recent-procedure or recent-therapy exclusions.No DRE within 4 days; no 5-alpha-reductase inhibitor therapy or invasive treatment for symptomatic benign prostatic hypertrophy within 6 months

    Not Covered Circumstances

    4K Score testing is not covered for patients with a previous prostate cancer diagnosis, a DRE within the previous 4 days, 5-alpha-reductase inhibitor therapy within the previous 6 months, or invasive treatment for symptomatic benign prostatic hypertrophy within the previous 6 months. Testing is also rarely indicated when life expectancy is less than 10 years and is intended only to aid the decision to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or a suspicious DRE.

    Policy Summary
    PayerVentura County Health Care Plan
    Policy4K Score Testing
    Policy CodePolicy 001
    Change TypeMaterial revision
    Effective DateNov 14, 2019
    Last ReviewFeb 12, 2026
    Next Review DateN/A
    Key ActionUse 4K Score testing to aid the decision whether to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or a suspicious digital rectal exam.
    SourceLink
    On This Page
    Coverage CriteriaTiming and Utilization ParametersProvider Action RequiredClinical BackgroundKey DefinitionsCovered Intended UseNot Covered Circumstances
    Testing is not intended when this therapy was received within the previous 6 months
    Interval after invasive treatment for symptomatic benign prostatic hypertrophy
    RequirementNo invasive treatment for symptomatic benign prostatic hypertrophy in the previous 6 months
    Restricted eventInvasive treatment for symptomatic benign prostatic hypertrophy
    Coverage implicationTesting is not intended when this treatment occurred within the previous 6 months
    Life expectancy
    ThresholdLess than 10 years of life expectancy
    Clinical consideration4K Score testing is rarely indicated below this life-expectancy threshold
    Coverage implicationLife expectancy should be considered before ordering the test
    Denial Risk

    Use Only for the Intended Indication

    Use the test only for its intended purpose: to aid the decision whether to proceed with prostate biopsy or MRI in men with elevated PSA levels and/or a suspicious DRE. Use outside this population or purpose may create denial risk.

    • Patient population: men with elevated PSA levels and/or suspicious DRE
    • Intended decision: whether to proceed with prostate biopsy or MRI
    Whether prostate nodules are present or absent
    Role in 4K ScoreDRE findings are incorporated into the score algorithm